AgomAb Therapeutics NV

Healthcare · Biotechnology · Belgium

Last price 7.49 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 368.87M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company’s product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFβR1 for the treatment of Fibrostenosing Crohn’s disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFβR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 cli...